Risk of birth defects by pregestational type 1 or type 2 diabetes: National Birth Defects Prevention Study, 1997-2011.


Journal

Birth defects research
ISSN: 2472-1727
Titre abrégé: Birth Defects Res
Pays: United States
ID NLM: 101701004

Informations de publication

Date de publication:
01 Jan 2023
Historique:
revised: 03 05 2022
received: 18 03 2022
accepted: 16 05 2022
pmc-release: 01 01 2024
pubmed: 7 6 2022
medline: 25 1 2023
entrez: 6 6 2022
Statut: ppublish

Résumé

Previous studies found consistent associations between pregestational diabetes and birth defects. Given the different biological mechanisms for type 1 (PGD1) and type 2 (PGD2) diabetes, we used National Birth Defects Prevention Study (NBDPS) data to estimate associations by diabetes type. The NBDPS was a study of major birth defects that included pregnancies with estimated delivery dates from October 1997 to December 2011. We compared self-reported PGD1 and PGD2 for 29,024 birth defect cases and 10,898 live-born controls. For case groups with ≥5 exposed cases, we estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the association between specific defects and each diabetes type. We calculated crude ORs (cORs) and 95% CIs with Firth's penalized likelihood for case groups with 3-4 exposed cases. Overall, 252 (0.9%) cases and 24 (0.2%) control mothers reported PGD1, and 357 (1.2%) cases and 34 (0.3%) control mothers reported PGD2. PGD1 was associated with 22/26 defects examined and PGD2 was associated with 29/39 defects examined. Adjusted ORs ranged from 1.6 to 70.4 for PGD1 and from 1.6 to 59.9 for PGD2. We observed the strongest aORs for sacral agenesis (PGD1: 70.4, 32.3-147; PGD2: 59.9, 25.4-135). For both PGD1 and PGD2, we observed elevated aORs in every body system we evaluated, including central nervous system, orofacial, eye, genitourinary, gastrointestinal, musculoskeletal, and cardiac defects. We observed positive associations between both PGD1 and PGD2 and birth defects across multiple body systems. Future studies should focus on the role of glycemic control in birth defect risk to inform prevention efforts.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies found consistent associations between pregestational diabetes and birth defects. Given the different biological mechanisms for type 1 (PGD1) and type 2 (PGD2) diabetes, we used National Birth Defects Prevention Study (NBDPS) data to estimate associations by diabetes type.
METHODS METHODS
The NBDPS was a study of major birth defects that included pregnancies with estimated delivery dates from October 1997 to December 2011. We compared self-reported PGD1 and PGD2 for 29,024 birth defect cases and 10,898 live-born controls. For case groups with ≥5 exposed cases, we estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the association between specific defects and each diabetes type. We calculated crude ORs (cORs) and 95% CIs with Firth's penalized likelihood for case groups with 3-4 exposed cases.
RESULTS RESULTS
Overall, 252 (0.9%) cases and 24 (0.2%) control mothers reported PGD1, and 357 (1.2%) cases and 34 (0.3%) control mothers reported PGD2. PGD1 was associated with 22/26 defects examined and PGD2 was associated with 29/39 defects examined. Adjusted ORs ranged from 1.6 to 70.4 for PGD1 and from 1.6 to 59.9 for PGD2. We observed the strongest aORs for sacral agenesis (PGD1: 70.4, 32.3-147; PGD2: 59.9, 25.4-135). For both PGD1 and PGD2, we observed elevated aORs in every body system we evaluated, including central nervous system, orofacial, eye, genitourinary, gastrointestinal, musculoskeletal, and cardiac defects.
CONCLUSIONS CONCLUSIONS
We observed positive associations between both PGD1 and PGD2 and birth defects across multiple body systems. Future studies should focus on the role of glycemic control in birth defect risk to inform prevention efforts.

Identifiants

pubmed: 35665489
doi: 10.1002/bdr2.2050
pmc: PMC10582790
mid: NIHMS1935905
doi:

Substances chimiques

Prostaglandin D2 RXY07S6CZ2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-66

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCBDD CDC HHS
ID : U01 DD001224
Pays : United States
Organisme : CDC HHS
Pays : United States

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

BMJ Open. 2015 Nov 02;5(11):e009088
pubmed: 26525723
Clin Epidemiol. 2021 Jul 26;13:615-626
pubmed: 34345185
BMJ. 2006 Jul 22;333(7560):177
pubmed: 16782722
Am J Prev Med. 2015 Feb;48(2):154-161
pubmed: 25326417
Med Care. 2006 Feb;44(2):132-40
pubmed: 16434912
Diabetologia. 2017 Sep;60(9):1668-1677
pubmed: 28597075
N Engl J Med. 2017 Apr 13;376(15):1419-1429
pubmed: 28402773
Birth Defects Res A Clin Mol Teratol. 2003 Mar;67(3):193-201
pubmed: 12797461
Menopause. 2014 Aug;21(8):861-8
pubmed: 24496083
Obstet Gynecol. 2006 Sep;108(3 Pt 1):644-50
pubmed: 16946226
Acta Obstet Gynecol Scand. 2008;87(1):43-9
pubmed: 18158626
Diabetes Metab Res Rev. 2015 Oct;31(7):707-16
pubmed: 25899622
Nutr Metab Cardiovasc Dis. 2008 May;18(4):291-7
pubmed: 17433638
Am J Obstet Gynecol. 2020 Feb;222(2):176.e1-176.e11
pubmed: 31454511
Birth Defects Res A Clin Mol Teratol. 2010 Oct;88(10):769-78
pubmed: 20973049
Postgrad Med J. 2014 Jan;90(1059):13-7
pubmed: 24225940
BMJ Open Diabetes Res Care. 2021 Apr;9(1):
pubmed: 33888543
Am J Obstet Gynecol. 2013 Sep;209(3):239.e1-8
pubmed: 23711668
Endocrinol Metab Clin North Am. 2010 Sep;39(3):481-97
pubmed: 20723815
Birth Defects Res A Clin Mol Teratol. 2007 Oct;79(10):714-27
pubmed: 17729292
CMAJ Open. 2017 Sep 25;5(3):E729-E733
pubmed: 28947426
Congenit Anom (Kyoto). 2010 Jun;50(2):115-21
pubmed: 20184644
Natl Health Stat Report. 2013 Nov 1;(69):1-14
pubmed: 24988821
PLoS One. 2020 Aug 18;15(8):e0237571
pubmed: 32810195
Diabetes Care. 2005 Feb;28(2):323-8
pubmed: 15677787
Birth Defects Res. 2020 Jan 15;112(2):186-195
pubmed: 31774241
J Obstet Gynaecol Can. 2009 Jun;31(6):487-496
pubmed: 19646313
Birth Defects Res A Clin Mol Teratol. 2015 Aug;103(8):656-69
pubmed: 26033852
Am J Obstet Gynecol. 2008 Sep;199(3):237.e1-9
pubmed: 18674752
BMC Pregnancy Childbirth. 2006 Oct 30;6:30
pubmed: 17074087

Auteurs

Stephanie L Marchincin (SL)

Birth Defects Registry, New York State Department of Health, Albany, New York, USA.

Meredith M Howley (MM)

Birth Defects Registry, New York State Department of Health, Albany, New York, USA.

Alissa R Van Zutphen (AR)

Birth Defects Registry, New York State Department of Health, Albany, New York, USA.
Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Albany, New York, USA.

Sarah C Fisher (SC)

Birth Defects Registry, New York State Department of Health, Albany, New York, USA.

Eirini Nestoridi (E)

Massachusetts Center for Birth Defects Research and Prevention, Boston, Massachusetts, USA.

Sarah C Tinker (SC)

National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Marilyn L Browne (ML)

Birth Defects Registry, New York State Department of Health, Albany, New York, USA.
Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Albany, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH